Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

Clinical trial NCT06757855 · RECRUITING

Trial details

NCT number: NCT06757855
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

CML,Blast Phase

Start date: 2025-01-26
Primary completion: 2026-12-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.